Status: Recruiting
CAR-T Cell Therapy, Mosunetuzumab and Polatuzumab for Treatment of Refractory/Relapsed Aggressive Non-Hodgkin's Lymphoma (NHL).
The purpose of this research study is to test if a combination treatment of chimeric antigen receptor (CAR) T-cell therapy, Mosunetuzumab, and Polatuzumab Vedotin will result in tumor reduction.
Participants needed: 22
Trial details
Phase: Phase 2Age: 18-80Biological sex: AllType: InterventionalSponsor: Lazaros LekakisUpdated: Dec 31, 2025Locations: 1
Eligibility criteria
Diffuse large B cell lymphoma (DLBCL) not otherwise specified. Patients with pri... [+24]
Patients with EBV+DLBCL, plasmablastic lymphoma, human herpesvirus-8 (HHV-8) rel... [+26]